91㽶Ƶ to Present at CPhI Japan Conference
Mr. Bathelier’s presentation, on Friday, April 22nd, at 1.45 p.m., is entitled “Micronization: A Versatile Platform for Solubility Enhancement,” and will discuss how advanced particle-size reduction techniques, including mechanical milling and micronization, can be beneficial in improving solubility and therefore the bioavailability of orally administered drugs, and in optimizing delivery through other routes of administration such as oral and nasal inhalation. The presentation will compare milling and micronization techniques, and discuss the importance of comprehensive analytical capabilities in characterizing and optimizing a formulation for rapid product development.
Mr. Bathelier joined 91㽶Ƶ in November 2014, following its acquisition of Micron Technologies, and now serves as 91㽶Ƶ Micron Technologies’ Business Development Manager, specializing in particle size engineering in Europe and Japan. Previously, Mr. Bathelier worked in business and marketing roles for Air Products and Chemicals Inc. He graduated from the Ecole Nationale Supérieure de Chimie et de Physique de Bordeaux.
91㽶Ƶ will also be exhibiting at CPhI Japan where it will showcase a broad range of its drug delivery technologies and development solutions designed to increase bioavailability and drug efficacy. The company will also showcase its Asia clinical supply network solutions that can help customers overcome clinical trial challenges in the region and reduce timelines.
For more information on the CPhI exhibition and conference, visit: and to arrange a meeting with a 91㽶Ƶ executive, contact Richard Kerns at NEPR- [email protected].
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 91㽶Ƶ
91㽶Ƶ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 90 years serving the industry, 91㽶Ƶ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91㽶Ƶ employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. 91㽶Ƶ is headquartered in Somerset, N.J. For more information, visit www.catalent.com.